期刊文献+

氟康唑治疗孢子丝菌病的临床疗效及体外抗真菌药敏试验研究 被引量:1

Evaluation of the Clinical Efficacy of Fluconazole to Sporotrichosis and the Antifungal Susceptibility in Vitro
下载PDF
导出
摘要 目的观察氟康唑对孢子丝菌病的临床疗效,检测孢子丝菌对氟康唑、伊曲康唑的体外敏感性,探讨孢子丝菌病治疗的新方法。方法对60例孢子丝菌病患者给予氟康唑片口服治疗[成人首次100mg,以后50mg,儿童3~5mg/(kg.d)],30例患者给予10%碘化钾溶液10mL口服治疗,并采用E-test法检测其中10株孢子丝菌对氟康唑和伊曲康唑的最小抑菌浓度(MIC)。结果氟康唑组有效率为95.00%,碘化钾组为86.67%。采用E-test法检测10株孢子丝菌对氟康唑和伊曲康唑的MIC值,范围分别为>256μg/mL,0.012~8.0μg/mL。结论氟康唑对孢子丝菌病有较好的临床疗效,但申克氏孢子丝菌对对氟康唑的体外敏感性较低。E-test法可以作为一种孢子丝菌的体外抗真菌药敏试验方法。 Objective To investigate the clinical efficacy of fluconazole in the treatment of Sporotrichosis and the susceptibility of fluconazole and itraconazole to Sporothrix schenckii in vitro, to study a new method in the treatment of Sporotrichosis. Methods 60 cases of patients with Sporotrichosis were given fluconazole tablets for three months . As a control, 30 patients with Sporotrichosis were given 10% KI for three months. The MIC of fluconazole and itraconazole for 10 isolates of Sporothrix schenckii were determined by the E-test. Results The effective rate of treatment and control group were 95.00% and 86.67% respectively. The MICs of fluconazole and itraconazole tothe 10 clinical isolates determined by the E-test were 〉 256μg/ml and 0.012 8.0μg/ml respectively. Conclusions The studies suggest that fluconazole is an effective method in the treatment of Sporotrichosis. E-test may be a good test for determining antifungal susceptibility of some antifungal agents to Sporothrix schenckii.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2010年第2期129-130,共2页 The Chinese Journal of Dermatovenereology
关键词 孢子丝菌病 氟康唑 抗真菌药敏试 伊曲康唑 Sporotrichosis Fluconazole Antifungal susceptibility testing Itraconzole
  • 相关文献

参考文献6

  • 1National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2002.
  • 2滕盛科,陆爱权,韦仁锋,张尤亮.上肢皮肤固定型孢子丝菌病2例[J].中国皮肤性病学杂志,2008,22(1):59-59. 被引量:3
  • 3李小环,李招群.国产氟康唑治疗念珠菌性外阴阴道炎100例疗效观察[J].临床皮肤科杂志,1995,24(1):33-34. 被引量:15
  • 4Colombo A, Barchiesi F, Mcgough DA, et al. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution for azol antifungal susceptibility testing [ J ]. J Clin Microbiol, 1995, 33(3) : 535 -540.
  • 5Mcginnis MR, Nordoff N, LIRK, et al. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B [ J ]. Med Mycol, 2001, 39 (4) : 369 -371.
  • 6Sharker-Mathis PK, Kauffman CA, Graybill J R, et al. Treatment of sporotriehosis with itraconazole [ J ]. Am J Med, 1993, 95 (3) : 279 - 285.

共引文献15

同被引文献22

  • 1Tellez MD,Batista-Duharte A,Portuondo D,et al.Sporothrix schenckii complex biology:environment and fungal pathogenicity[J].Microbiology,2014,160(11):2352-2365.
  • 2Marimon R,Gene J,Cano J,et al.Molecular phylogeny of Sporothrix schenckii[J].J Clin Microbiol,2006,44(9):3251-3256.
  • 3Yu X,Wan Z,Zhang Z,et al.Phenotypic and molecular identification of Sporothrix isolates of clinical origin in Northeast China[J].Mycopathologia,2013,176(1-2):67-74.
  • 4Mahajan VK.Sporotrichosis:an overview and therapeutic options[J].Dermatol Res Pract,2014,2014(2013):272376.
  • 5Ottonelli Stopiglia CD,Magagnin CM,Castrillon MR,et al.Antifungal susceptibilities and identification of species of the Sporothrix schenckii complex isolated in Brazil[J].Med Mycol,2014,52(1):56-64.
  • 6Kauffman CA,Bustamante B,Chapman SW et al,Clinical practice guidelines for the management of sporotrichosis:2007 update by the Infectious Diseases Society of America[J].Clin Infect Dis,2007,45(10):1255-1265.
  • 7Stopiglia,CD,Marchese DP,Heidrich D,et al,Comparison between two culture media for in vitro evaluation of antifungal susceptibility of the Sporothrix schenckii complex[J].An Bras Dermatol,2012,87(4):561-565.
  • 8Kohler LM,Soares BM,de Assis Santos D,et al.In vitro susceptibility of isolates of Sporothrix schenckii to amphotericin B,itraconazole,and terbinafine:comparison of yeast and mycelial forms[J].Can J Microbiol,2006,52(9):843-847.
  • 9Borba-Santos LP,Rodrigues AM,Gagini TB,et al.Susceptibility of Sporothrix brasiliensis isolates to amphotericin B,azoles,and terbinafine[J].Med Mycol,2015,53(2):178-188.
  • 10Chapman SW,Pappas P,Kauffmann C,et al.Comparative evaluation of the efficacy and safety of two doses of terbinafine(500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis[J].Mycoses,2004,47(1-2):62-68.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部